Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin vs Enoxaparin for VTE Prevention in Arthroplasty
NCT06635317Phase 4Completed
- Sponsor
- ISSSTE
- Start
- Apr 2022
- Primary completion
- Oct 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in venous thromboembolism (VTE) (2 arms), sponsored by ISSSTE. Primary endpoint: Symptomatic Venous Thromboembolism at 90 days. Started Apr 2022; status: completed.
02
Drugs
aspirin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06635317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635317.